Administration reaches deal with AstraZeneca on lowering drug costs
The White House Oct. 10 announced it reached an agreement with AstraZeneca to align drug prices with the lowest paid by other developed nations, also known as the most-favored-nation price. Like the administration’s agreement with Pfizer, AstraZeneca will provide every state Medicaid program in the country access to MFN drug prices on its products and will be required to offer medicines at deep discounts off the list price when selling directly to Americans. AstraZeneca said in a news release that it will also have a three-year exemption from tariffs on their products and will sell products on the TrumpRX platform. In addition, AstraZeneca will invest $50 billion in U.S. manufacturing and research and development by 2030.
Related News Articles
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The Food and Drug Administration recently disclosed dozens of warning letters sent to drug companies that accuse them of using misleading or deceptive…
Headline
President Trump Sept. 10 signed a memorandum directing the Department of Health and Human Services and Food and Drug Administration to require drug companies…
Headline
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by increasing regulatory…
Headline
A JAMA Internal Medicine study published April 7 examined the effects of changing the default prescription lengths for statins, which are cholesterol-lowering…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…